From the Miami Herald:
Bush re-election gives struggling drugmakers status quo benefits
The pharmaceutical industry stands to benefit from President Bush's re-election, but it's from maintenance of the status quo rather than any new policies favoring drug makers.

"In the scheme of things, it doesn't have any meaningful impact on the industry," said independent pharmaceuticals analyst Hemant Shah of HKS & Co. in Warren, N.J.

Industry analysts say that with Bush still in the White House and Republicans tightening their control of Congress, government price controls for prescription medicines won't be on the table. The free-market system, where demand drives price, will continue, said Barbara Ryan, a pharmaceuticals analyst and managing director at Deutsche Bank Securities.